 |
 |
| |
1) |
°ñ°üÀý¿°Àº »ç¶÷¿¡¼ 70% Á¤µµÀÇ
¹ß»ýÀ²(> 65years) (LingSMetal,1998), °³¿¡¼ 20% Á¤µµÀÇ ¹ß»ý·ü (>1
years) (JohnstonSAetal,1997)À» º¸ÀÌ´Â °ÍÀ¸·Î º¸°í µÇ°í ÀÖ´Ù. |
| |
2) |
°ñ°üÀý¿°Àº Á¶±â¿¡ Ä¡·á°¡ À¯¿ëÇÑ °ÍÀ¸·Î º¸°í µÇ°í
ÀÖÀ¸³ª ¾ÆÁ÷±îÁö Áø´ÜÀûÀ¸·Î ¾²À̰í ÀÖ´Â ¹æ»ç¼±°ú ÀÓ»óÁõ»ó¸¸À¸·Î´Â Á¶±â Áø´ÜÀº ¾î·Á¿î ½ÇÁ¤ÀÌ´Ù. |
| |
3) |
ÀÌ¿¡ °³ÀÇ »õ·Î¿î °ñ°üÀý¿° ¸ðµ¨À» ¸¸µé°í Á¶±âÁø´ÜÀÎÀÚ·Î
¾²ÀÏ ¼ö ÀÖ´Â »ý¹°ÇÐÀûÀÎ ÁöÇ¥¸¦ ã´Â´Ù. |
 |
| |
1) |
µ¿¹° Àü¿ë implantÀÇ ½ÃÀ强 ¹× »çȸÀû ¿ä±¸
Áõ°¡ |
| |
2) |
ÇöÀç »ç¿ëµÇ´Â implant´Â ´ëºÎºÐ ¼öÀÔ¿¡ ÀÇÁ¸ |
| |
3) |
»ýüÀûÇÕ¼ºÀÇ »õ·Î¿î implantÀÇ °³¹ß |
| |
4) |
»ýüÀûÇÕ¼ºÀÌÁ¾°ñÀ»ÀÌ¿ëÇÑ»õ·Î¿î implantÀÇ °³¹ß |
|
|
 |
- ¼öÀÇÇаú ¿Ü°úÇÐ½Ç ±³¼ö ÃÖ ÀÎ Çõ
- ¼öÀÇÇаú ¿Ü°úÇÐ½Ç ±³¼ö ±è ³² ¼ö
- ¼öÀÇÇаú ¿Ü°úÇÐ½Ç ¹Ú»ç°úÁ¤ ÀÌ ÇØ ¹ü
- ¼öÀÇÇаú ¿Ü°úÇÐ½Ç ¹Ú»ç°úÁ¤ ¾Ë ¶÷
- ¼öÀÇÇаú ¿Ü°úÇÐ½Ç ¹Ú»ç°úÁ¤ °í Àç Áø
- ¼öÀÇÇаú ¿Ü°úÇÐ½Ç ¹Ú»ç°úÁ¤ ÃÖ À± ±â |
- ¼öÀÇÇаú ¿Ü°úÇÐ½Ç ¼®»ç°úÁ¤ ½Å ½Â
È£
- ¼öÀÇÇаú ¿Ü°úÇÐ½Ç ¼®»ç°úÁ¤ Çã ¼ö ¿µ
- ¼öÀÇÇаú ¿Ü°úÇÐ½Ç ¼®»ç°úÁ¤ ÀÌ ¼¼ ¿µ
- ¼öÀÇÇаú ¿Ü°úÇÐ½Ç ¼®»ç°úÁ¤ ±è ÁÖ È£
- ¼öÀÇÇаú ¿Ü°úÇÐ½Ç ¼®»ç°úÁ¤ ¼Ò °æ ¹Î |
|
|
|
 |
| |
1) |
The study of Early
Biomarker and Treatment in Canine Osteoarthritis Model |
| |
2) |
Evaluation of the stifle joint
after ACLT, MCLT and MNT without postoperative exercise |
| |
3) |
Assessment of TRAP activity,
MMP-2 and TIMP-2 as biomarker in early stage canine osteoarthritis |
| |
4) |
Effects of orally administered
celecoxib and glucosamine hydrochloride and chodroitin
sulfate on MMP-2,9, TIMP-2 and TRAP activity in canine
osteoarthritis model |
| |
5) |
Effects of Ratio of Gel-formed
Hydroxyapatite-Chitosan Composites on the Bone Defect
of Canine Model |
| |
6) |
The effects of chitin derivative
and hydroxyapatite compound in canine bone |
| |
7) |
Effectiveness of bone plate
make of a allograft cortical bone for internal fixation
in fracture model of dogs |
| |
8) |
Biomechanical Assessment of
Freeze-Dried Allograft Cortical Bone plate Graft in Canine
Bone Defect Model |
 |
üÄÚ ÇÁ¶óÇÏ¿¡¼ ¿¸° 2006 ¼¼°è ¼Òµ¿¹°¼öÀÇ»çȸ
(WSAVA)¿¡ ¿Ü°úÇб³½ÇÀÇ ±è³²¼ö±³¼ö,
ÀÌÇØ¹ü, ½Å½ÂÈ£µîÀÌ Âü¼®ÇÏ¿© °ñ°üÀý¿° ¸ðµ¨ÀÇ Á¶±â Áø´Ü ÀÎÀÚ¿¡ °üÇÑ Æ÷½ºÅÍ 2Æí°ú
¼±ÃµÀû±âÇü (¿°»öü ÀÌ»ó) Æ÷½ºÅ͸¦ ¹ßÇ¥. |
|
| |
 |
| Áß±¹ ¼ºµµ¿¡¼ ¿¸° 2006³â ±¹Á¦ °ñ´Ù°øÁõ
ÇÐȸ¿¡ Âü¼®ÇÏ¿© ¿Ü°úÇб³½Ç ±è³²¼ö±³¼ö, ¾Ë¶÷, Çã¼ö¿µ, ±èÁÖÈ£, ¼Ò°æ¹ÎµîÀÌ Âü¼®ÇÏ¿© °ñ´Ù°øÁõ
À¯¹ß¸ðµ¨¿¡¼ ȫȾ¾ÀÇ Ä¡·á È¿°ú¿¡ °üÇÑ ¿¬±¸¸¦ ±¸µÎ ¹ßÇ¥ÇÏ¿© ¿ì¼ö ¹ßÇ¥»óÀ» ¼ö»ó. |
|
| |
 |
| °³¿¡¼ ¼ö¼úÀû ¹æ¹ýÀ¸·Î °üÀý¿°À» À¯¹ßÇÏ¿©
°ñ°üÀý¿° ¸ðµ¨À» È®¸³ÇÑ ÈÄ »ý¹°ÇÐÀû Ç¥½ÃÀÎÀÚÀÎ ACLT, MCLT and MNT TRAP
activity, MMP-2 and TIMP-2À» ÃøÁ¤ÇÏ°í °üÀý¿°ÀÇ »õ·Î¿î Ä¡·áÁ¦ (celecoxib
and glucosamine hydrochloride) ¸¦ ÀÌ¿ëÇÏ¿© °üÀý¿°ÀÇ Á¶±â Áø´Ü
ÀÎÀÚÀÇ À¯¿ë¼ºÀ» Æò°¡ÇÏ¿© °üÀý¿° Áø´Ü ¹× Ä¡·á¿¡ Å« ±â¿©¸¦ ÇÒ °ÍÀ¸·Î ÆÇ´ÜµÊ. |
|